Business
Takeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consist
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies","length":140,"tagName":"p"}]},{"val":[{"type":"text","content":"A significantly greater PASI 75 response rate versus placebo was observed as early as week 4","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"Safety profile consistent with Phase 2b studies with no new safety signals identified","length":85,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":317,"olType":false},{"type":"text","content":"TORONTO, March 31, 2026 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2","length":576,"tagName":"p"},{"type":"image","alt":"Takeda Canada Logo (CNW Group/Takeda Canada Inc.)","displaySize":"","headline":null,"caption":"Takeda Canada Logo (CNW Group/Takeda Canada Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":210,"url":"https://media.zenfs.com/en/cnwgroup.com/88173a8e0055be61919c82ca4ec68cd1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QHXZ3Inu10LeolDxoOiMLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM3MA--/https://media.zenfs.com/en/cnwgroup.com/88173a8e0055be61919c82ca4ec68cd1","width":400,"height":210}},"href":"https://mma.prnewswire.com/media/2946075/Takeda_Canada_Inc__Takeda_s_Zasocitinib_Delivered_Rapid_and_Dura.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies," said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. "These efficacy and safety results show it's possible for a once-d...